SCHEMBL648238

SCHEMBL648238

CCCCn1c(-c2ccccc2)nc(-c2ccc(OC)cc2)c1CN(Cc1ccc2[nH]ncc2c1)CC1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.38
ROCK2 O75116 7/20 0.36
ROCK1 Q13464 4/20 0.36
CCR2 P41597 3/20 0.36
BCHE P06276 3/20 0.36
GRIN2B Q13224 1/20 0.36
MEN1 O00255 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GRIA1 P42261 1/20 0.33
ADORA1 P30542 2/20 0.33
ADORA2B P29275 1/20 0.33
AURKA O14965 1/20 0.33
CHUK O15111 1/20 0.33
MAPK13 O15264 1/20 0.33
DAPK3 O43293 1/20 0.33
JAK2 O60674 1/20 0.33
CHEK2 O96017 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650156 0.94 C5AR1 (0.42) C5AR1ROCK2ROCK1GRIN2BAURKA
SCHEMBL5137557 0.88 C5AR1 (0.42) C5AR1BCHEMEN1HTTKMT2A
SCHEMBL5137356 0.84 MEN1 (0.45) C5AR1MEN1KMT2ASMN1; SMN2ADORA1
SCHEMBL648304 0.84 C5AR1 (0.41) C5AR1BCHEMEN1KMT2AADORA1
SCHEMBL4766337 0.84 C5AR1 (0.38) C5AR1BCHEMEN1HTTKMT2A
SCHEMBL648140 0.83 C5AR1 (0.44) C5AR1MEN1HTTKMT2ASMN1; SMN2
SCHEMBL4769327 0.83 C5AR1 (0.44) C5AR1BCHE
SCHEMBL648105 0.83 C5AR1 (0.38) C5AR1BCHEMEN1HTTKMT2A
SCHEMBL5135713 0.83 C5AR1 (0.44) C5AR1ADORA1ADORA2BMAPK1ADORA3
SCHEMBL5136823 0.82 C5AR1 (0.42) C5AR1BCHEKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed